What question did this study set out to answer?

This research aims to update the efficacy and safety profile of tisagenlecleucel in treating pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia.

November 29, 2018Blood

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

View Full Paper

Ask AI

Bookmark

Authors

SGStephan A. GruppUniversità Cattolica del Sacro Cuore SMShannon L. MaudeChildren's Hospital of Philadelphia SRSusana RivesHospital Sant Joan de Déu Barcelona

Discussion

Member takes

Implication

Randomized trial evaluates efficacy and safety of tisagenlecleucel in pediatric/young adult patients with r/r ALL, suggesting effective treatment options.

Key Points

This research aims to update the efficacy and safety profile of tisagenlecleucel in treating pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia.
Analyzed data from the ELIANA study (NCT02435849) with 97 enrolled patients.
Patients received a single infusion of tisagenlecleucel following lymphodepleting chemotherapy.
Primary endpoint assessed was overall remission rate (ORR) within three months post-infusion.
Achieved an overall remission rate (ORR) of 81% with 64 out of 65 patients in CR/CRi.
Probability of relapse-free survival at 18 months was 66% (95% CI, 52%-77%).
Median overall survival (OS) was not reached, with OS probability at 18 months being 70% (95% CI, 58%-79%).

Cite This Study

Grupp et al. (2018) studied this question.

synapsesocial.com/papers/6a105cee90ecb39bf65fd95d https://doi.org/10.1182/blood-2018-99-112599

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates efficacy and safety of tisagenlecleucel in pediatric/young adult patients with r/r ALL, suggesting effective treatment options.

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider